Pharma Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Head Lice
PerFoam demonstrates safety and 96% efficacy in phase II/III study
August 15th, 2005
Foamix, Ltd., announced the results of its phase II/III study of one of its lead products, PerFoam, for the treatment of lice. Trial data shows evidence of safety and a 96% efficacy rate. Foamix anticipates launching PerFoam in the Israeli market in 2006, and in the global market in 2006/7. PerFoam, comprised of 1% Permethrin and 2 proprietary enhancers, is an alcohol-free, nonirritating, drip-free foam for the treatment of head lice. The study, titled "An open study to assess the efficacy, safety and usability of a 1% Permethrin Foam, in the treatment of head lice (pediculosis capitis) in pediatric patients," was conducted at the Laniado Medical...
Source: Pharma Business Week (2005-08-15)
|
